Barclays lowered the firm’s price target on Charles River (CRL) to $145 from $160 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River price target lowered to $155 from $175 at Mizuho
- Pfizer, Flagship Pioneerig partner for discovery of novel autoimmune compounds
- FedEx downgraded, Adobe upgraded: Wall Street’s top analyst calls
- Charles River downgraded to Neutral from Buy at Goldman Sachs
- Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904